Bifogade filer
PDF
Kurs
+3,38%
Kalender
| Est. tid* | ||
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-23 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | X-dag ordinarie utdelning RECI B 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-10 | - | Extra Bolagsstämma 2021 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2021-01-28 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-13 | - | X-dag ordinarie utdelning RECI B 0.00 SEK |
| 2020-05-12 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-07 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-25 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-14 | - | X-dag ordinarie utdelning RECI B 1.25 SEK |
| 2019-05-13 | - | Årsstämma |
| 2019-05-03 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-11-08 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-25 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-15 | - | X-dag ordinarie utdelning RECI B 0.00 SEK |
| 2018-05-14 | - | Årsstämma |
| 2018-04-27 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-09 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-11 | - | X-dag ordinarie utdelning RECI B 1.50 SEK |
| 2017-05-10 | - | Årsstämma |
| 2017-04-27 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-23 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-31 | - | Kapitalmarknadsdag 2016 |
| 2016-07-22 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-10 | - | Extra Bolagsstämma 2016 |
| 2016-04-29 | - | X-dag ordinarie utdelning RECI B 1.50 SEK |
| 2016-04-28 | - | Årsstämma |
| 2016-04-28 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-24 | - | Bokslutskommuniké 2015 |
| 2015-11-05 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-23 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-08 | - | X-dag ordinarie utdelning RECI B 1.25 SEK |
| 2015-05-07 | - | Årsstämma |
| 2015-05-07 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-19 | - | Bokslutskommuniké 2014 |
| 2014-11-07 | - | Analytiker möte 2014 |
| 2014-11-07 | - | Kvartalsrapport 2014-Q3 |
| 2014-09-11 | - | Extra Bolagsstämma 2014 |
| 2014-08-14 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-08 | - | Kvartalsrapport 2014-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Recipharm AB (publ) announces that Tobias Hägglöv takes office as new Chief Financial Officer, effective today. Tobias will be a member of Recipharm Group Management team and reports to Thomas Eldered, Chief Executive Officer of Recipharm.
Tobias Hägglöv has comprehensive experience in finance and management positions. He joins Recipharm from a position as the CFO at LEAX. Prior to that, Tobias Hägglöv served at Electrolux, SAS and Accenture. Tobias holds a degree in Finance and Business Administration from the University of Stockholm, and a M.Sc. from Royal Institute of Technology, Stockholm, Sweden.
Contact information
Thomas Eldered, CEO, telephone: +46 8 602 52 10, ir@recipharm.com
This information is information that Recipharm AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 3 October 2018, at 10:00 am CET.
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm's turnover is approximately SEK 6.0 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com